N-[(1S)-2-[4-(5-Chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1-methylethyl-2-naphthalenecarboxamide

VU0155069 is a potent and specific inhibitor of phospholipase D1.

vu 0155069 is a selective phospholipase d1 (pld1) inhibitor, with an ic50 value of 46 nm [1].pld1 is one of the main pld isoforms in mammals. pld is an important enzyme responsible for the production of the lipid second messenger, i.e. phosphatidic acid which participates in both g protein-coupled receptor and receptor tyrosine kinase signal transduction networks [1].in calu-1 and hek293-gfppld2 cells, vu 0155069 blocked both pld1 and pld2 activity at the concentration of 20 μm, whilst preferentially inhibited pld1 at a lower concentration of 200 nm. in 4t1 cells, pld1-preferring vu 0155069 at 200 nm significantly decreased cell migration compared with the vehicle control [1].in mice bearing hepatocellular carcinoma xenografts, vu 0155069 (5 mg/kg, 50 μl, s.c., on alternate days) significantly reduced xenograft tumor size and weight. furthermore, vu 0155069 treatment substantially reduced both proliferating cell nuclear antigen- (pcna-) and ki67-positive cell populations in skin xenograft tumors [2].[1]. scott s a, selvy p e, buck j r, et al. design of isoform-selective phospholipase d inhibitors that modulate cancer cell invasiveness. nature chemical biology, 2009, 5(2): 108-117.[2]. xiao j, sun q, bei y, et al. therapeutic inhibition of phospholipase d1 suppresses hepatocellular carcinoma. clinical science, 2016, 130(13): 1125-1136.

PLD1: 46 nM (IC₅₀); PLD2: 933 nM (IC₅₀)